France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its ...

French pharma major Sanofi delivered a set of first-quarter financial results that seemed to satisfy markets Thursday, as its ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), ...

France's Sanofi (SASY.PA), opens new tab reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as ...